NKGen Biotech to Present at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
SANTA ANA, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (“NKGen”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK Natural Killer (“NK”) cell therapeutics, today announced an upcoming presentation on its NK cell therapy (SNK01) at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting, which will take place in Los Angeles, California from May 16 - 20, 2023.
Presentation Title: SNK01 Autologous Enhanced Natural Killer Cells and an Immune Checkpoint Inhibitor Control Tumor Growth in Rare Chemotherapy-Resistant Advanced Soft Tissue Sarcomas
Presenting Author: Erlinda M. Gordon, M.D.
Session Type: Poster Presentation
Date & Time: Thursday, May 18, 2023; 12:00 p.m. – 2:00 p.m. PT
Abstract Number: 1136
Dr. Gordon will present data from three rare cases of chemotherapy-resistant advanced soft tissue sarcomas (STS) which achieved durable partial responses and disease control with SNK01 plus an immune checkpoint inhibitor. NKGen believes the data from these three cases support the potential combination of SNK01 and an immune checkpoint inhibitor in controlling tumor growth with manageable toxicity.
Full abstracts are available on the ASGCT conference website https://annualmeeting.asgct.org/
About NKGen Biotech
NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK Natural Killer (NK) cell therapeutics. NKGen is headquartered in Santa Ana, California, USA. For more information, please visit www.nkgenbiotech.com.
The forward-looking statements made in this press release relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the data on which the statements are made or to reflect the occurrence of unanticipated events. You should read this press release completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this press release, statements of, or references to, our intentions and expectations or those of Dr. Erlinda M. Gordon are made as of the date of this article. Any of these intentions and expectations may alter in light of future development.
Denise Chua, MBA, CLS, MT (ASCP)
Vice President, Investor Relations and Corporate Communications
Released May 2, 2023